Eupraxia Pharmaceuticals Inc.
EPRX
$7.51
-$0.07-0.92%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 56.56% | 27.11% | 29.40% | 33.64% | 45.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.33% | -5.55% | -8.50% | -11.52% | -3.03% |
| Operating Income | -42.33% | 5.55% | 8.50% | 11.52% | 3.03% |
| Income Before Tax | -49.89% | -2.17% | -4.84% | 15.33% | 11.02% |
| Income Tax Expenses | 961.11% | -73.63% | -71.98% | -100.97% | -95.05% |
| Earnings from Continuing Operations | -49.96% | -2.07% | -4.74% | 15.44% | 11.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -87.77% | -92.84% | -88.58% | -83.37% | -67.53% |
| Net Income | -51.26% | -4.09% | -7.25% | 13.65% | 9.63% |
| EBIT | -42.33% | 5.55% | 8.50% | 11.52% | 3.03% |
| EBITDA | -42.32% | 5.71% | 8.66% | 11.58% | 3.05% |
| EPS Basic | -29.71% | 4.25% | 8.56% | 36.01% | 34.11% |
| Normalized Basic EPS | -23.69% | 10.08% | 12.18% | 37.55% | 34.38% |
| EPS Diluted | -29.71% | 4.25% | 8.56% | 36.01% | 34.11% |
| Normalized Diluted EPS | -23.69% | 10.08% | 12.18% | 37.55% | 34.38% |
| Average Basic Shares Outstanding | 17.78% | 13.19% | 21.84% | 37.55% | 40.55% |
| Average Diluted Shares Outstanding | 17.78% | 13.19% | 21.84% | 37.55% | 40.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |